Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

BACKGROUND: To compare the efficacy of crizotinib, pemetrexed and other chemotherapy regimens as a first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in real world clinical use and to evaluate the +86–571-87,236,876 predictive clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jianya, Zheng, Jing, Zhang, Xiaochen, Zhao, Jing, Zhu, Yanping, Shen, Qian, Wang, Yuehong, Sun, Ke, Zhang, Zeying, Pan, Zhijie, Shen, Yihong, Zhou, Jianying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751674/
https://www.ncbi.nlm.nih.gov/pubmed/29298713
http://dx.doi.org/10.1186/s12885-017-3720-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751674/
https://www.ncbi.nlm.nih.gov/pubmed/29298713
http://dx.doi.org/10.1186/s12885-017-3720-8

Ejemplares similares